Human skin replacement - Stratatech

Drug Profile

Human skin replacement - Stratatech

Alternative Names: StrataGraft

Latest Information Update: 19 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Wisconsin System; Wisconsin Alumni Research Foundation
  • Developer Stratatech
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity No

Highest Development Phases

  • Phase III Burns
  • Phase II Wounds

Most Recent Events

  • 19 Jul 2017 The US FDA grants Regenerative Medicine Advanced Therapy status to StrataGraft
  • 04 May 2017 Phase-II clinical trials in Wounds in USA (Topical) (NCT03005054)
  • 04 May 2017 Stratatech initiates enrolment in a phase II trial for Burns in USA (NCT03005054)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top